biostudies-literaturePino MNational Institute of Allergy and Infectious DiseasesOffice of Public AffairsChildhood Infections and Vaccines Children Healthcare of Atlanta 712 Woodruff Health Sciences CenterNIAID NIH HHSBaylor UniversityYerkes National Primate Research Center, Emory UniversityNational Institutes of HealthScientific Advisory Board of MaxHealth 724 Biotechnology LLCNIH HHSeabh3634https://www.ebi.ac.uk/biostudies/studies/S-EPMC9119307biostudies-literatureUnknown6(61)Ongoing SARS-CoV-2 vaccine development is focused on identifying stable, cost-effective, and accessible candidates for global use, specifically in low and middle-income countries. Here, we report the efficacy of a rapidly scalable, novel yeast expressed SARS-CoV-2 specific receptor-binding domain (RBD) based vaccine in rhesus macaques. We formulated the RBD immunogen in alum, a licensed and an emerging alum adsorbed TLR-7/8 targeted, 3M-052-alum adjuvants. The RBD+3M-052-alum adjuvanted vaccine promoted better RBD binding and effector antibodies, higher CoV-2 neutralizing antibodies, improved Th1 biased CD4+T cell reactions, and increased CD8+ T cell responses when compared to the alum-alone adjuvanted vaccine. RBD+3M-052-alum induced a significant reduction of SARS-CoV-2 virus in respiratScience immunologyA yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.PMC911930775N9301900065222063U19AI057266-17S1U19 AI057266TLR-7/8 723US 2019/0142935P51 OD011132U19 AI090023HHSN272201800004C2020 COVID-19 CURE AP30 A050509ORIP/OD P51OD0111323U19AI057266-715HIPC COVID-19 SCOVID-19 RBDP51-OD011132U19AI090023Pacheco-Sanchez GGumber SJean SMSette APaiardini MPollara JMielke DLee JGao HWood JSSuthar MSAbid TLiu ZDutta DEdara VVWang SStrych UShenvi NSekaly RPHotez PJMontefiori DCStammen RLWei JShen XSmith JCConnor-Stroud FKasturi SPVanderford THPollet JZhan BLatif MBTomai MAPereira Ribeiro SFerrari GBottazzi MEFloyd KWeiskopf DKozlowski PAKirejczyk SLaBranche CCFox CBChen WHEasley KPino MEisel NCohen JTomaras GDfalseA yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.Ongoing SARS-CoV-2 vaccine development is focused on identifying stable, cost-effective, and accessible candidates for global use, specifically in low and middle-income countries. Here, we report the efficacy of a rapidly scalable, novel yeast expressed SARS-CoV-2 specific receptor-binding domain (RBD) based vaccine in rhesus macaques. We formulated the RBD immunogen in alum, a licensed and an emerging alum adsorbed TLR-7/8 targeted, 3M-052-alum adjuvants. The RBD+3M-052-alum adjuvanted vaccine promoted better RBD binding and effector antibodies, higher CoV-2 neutralizing antibodies, improved Th1 biased CD4+T cell reactions, and increased CD8+ T cell responses when compared to the alum-alone adjuvanted vaccine. RBD+3M-052-alum induced a significant reduction of SARS-CoV-2 virus in respirat2021-01-01T00:00:00Z2021 Jul2026-05-09T15:04:56.79Z2025-04-04T08:38:53.627ZS-EPMC91193073426698110.1126/sciimmunol.abh3634